Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.66 [0.51, 0.86] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | crucial | - |
objective responses (ORR) | 8.24 [1.85, 36.76] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.99 [0.24, 4.05] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.95 [0.59, 1.55] | | < 1 | | 0% | 1 study (1/-) | 57.5 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.09 [0.60, 1.98] | | < 1 | | 0% | 1 study (1/-) | 39.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.41 [0.69, 2.88] | | < 1 | | 0% | 1 study (1/-) | 17.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 14.85 [0.83, 264.38] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 6.29 [0.75, 52.98] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
Endocrine disorders TRAE (grade 3-4) | 10.44 [0.56, 193.00] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 10.83 [1.37, 85.84] | | < 1 | | 0% | 1 study (1/-) | 1.2 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 0.16 [0.01, 3.32] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 4.08 [0.18, 91.29] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 2.02 [0.07, 60.83] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.08 [0.18, 91.29] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
Vitiligo TRAE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.28 [0.06, 1.36] | | < 1 | | 0% | 1 study (1/-) | 94.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.35 [0.11, 1.12] | | < 1 | | 0% | 1 study (1/-) | 96.2 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 3.07 [0.32, 29.91] | | < 1 | | 0% | 1 study (1/-) | 16.9 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 1.01 [0.02, 51.17] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.50 [0.09, 2.76] | | < 1 | | 0% | 1 study (1/-) | 78.8 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 7.40 [0.90, 60.98] | | < 1 | | 0% | 1 study (1/-) | 3.2 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 0.83 [0.25, 2.80] | | < 1 | | 0% | 1 study (1/-) | 61.6 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 2.36 [0.71, 7.87] | | < 1 | | 0% | 1 study (1/-) | 8.1 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 1.01 [0.20, 5.09] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 1.01 [0.20, 5.09] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.25 [0.01, 5.58] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 1.01 [0.20, 5.09] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |